214 related articles for article (PubMed ID: 28425505)
1. Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors.
Minervini G; Lopreiato R; Bortolotto R; Falconieri A; Sartori G; Tosatto SCE
Sci Rep; 2017 Apr; 7():46562. PubMed ID: 28425505
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. Insights into the molecular features of the von Hippel-Lindau-like protein.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
Amino Acids; 2019 Nov; 51(10-12):1461-1474. PubMed ID: 31485743
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
5. Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development.
Limaverde-Sousa G; Barreto Ede A; Ferreira CG; Casali-da-Rocha JC
Proteins; 2013 Feb; 81(2):349-63. PubMed ID: 23011899
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
7. A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein.
Bex C; Knauth K; Dambacher S; Buchberger A
Nucleic Acids Res; 2007; 35(21):e142. PubMed ID: 17986458
[TBL] [Abstract][Full Text] [Related]
8. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q
Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792
[TBL] [Abstract][Full Text] [Related]
9. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
10. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.
Mack FA; Patel JH; Biju MP; Haase VH; Simon MC
Mol Cell Biol; 2005 Jun; 25(11):4565-78. PubMed ID: 15899860
[TBL] [Abstract][Full Text] [Related]
11. Effects of point mutations in pVHL on the binding of HIF-1α.
Domene C; Illingworth CJ
Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
[TBL] [Abstract][Full Text] [Related]
12. Design and analysis of a Petri net model of the Von Hippel-Lindau (VHL) tumor suppressor interaction network.
Minervini G; Panizzoni E; Giollo M; Masiero A; Ferrari C; Tosatto SC
PLoS One; 2014; 9(6):e96986. PubMed ID: 24886840
[TBL] [Abstract][Full Text] [Related]
13. In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: a new player in the VHL/HIF-1α interaction pathway?
Minervini G; Masiero A; Moro S; Tosatto SC
FEBS Lett; 2013 Sep; 587(18):2996-3001. PubMed ID: 23886708
[TBL] [Abstract][Full Text] [Related]
14. Immunoexpression patterns for Hypoxia-inducible Factor-1α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors.
Assimakopoulou M; Androutsopoulou C; Zolota V; Matsoukas J
Histol Histopathol; 2016 May; 31(5):535-46. PubMed ID: 26592496
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
PLoS Comput Biol; 2019 Apr; 15(4):e1006478. PubMed ID: 30943211
[TBL] [Abstract][Full Text] [Related]
16. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL.
Kim JA; Choi DK; Min JS; Kang I; Kim JC; Kim S; Ahn JK
FEBS J; 2018 Jan; 285(1):115-126. PubMed ID: 29121446
[TBL] [Abstract][Full Text] [Related]
17. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination.
Jung JE; Kim HS; Lee CS; Shin YJ; Kim YN; Kang GH; Kim TY; Juhnn YS; Kim SJ; Park JW; Ye SK; Chung MH
Exp Mol Med; 2008 Oct; 40(5):479-85. PubMed ID: 18985005
[TBL] [Abstract][Full Text] [Related]
18. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1α and hierarchical quality control of pVHL via chaperone system.
Ni J; Ni A
PLoS One; 2021; 16(7):e0248019. PubMed ID: 34329303
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]